$2.210
-0.068 (-3.07%)Al cierre
- High
- 2.300
- Open
- 2.270
- VWAP
- 2.21
- Vol
- 798.26K
- Mkt Cap
- —
- Low
- 2.130
- Amount
- 1.77M
- EV/EBITDA, TTM
- 0.00
NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in developing treatments to promote nervous system repair in the settings of neurotrauma and neurologic disease. NVG-291 is in a Phase 1b/2a clinical trial in spinal cord injury and has undertaken preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI). Its NVG-291 is a therapeutic peptide targeting nervous system repair.
AI analysis of NervGen Pharma Corp (NGEN)
buyNervgen Pharma appears to be a good buy right now, given its current price of $2.28, a recent RSI of 83.719 indicating strong momentum, and a projected price target of $15 from H.C. Wainwright. The positive catalysts include a public offering that raised $60 million for clinical studies and a Buy rating from TD Cowen, projecting peak sales of $1.1 billion for NVG-291. However, the main risk is the significant year-to-date change of -63.52%, indicating past volatility and potential investor concerns.
Métricas de valoración
Cronología de eventos
Noticias
9.508-13NewsfilterNervGen Reports Q2 2026 Financial Results and Progress Updates
8.506-11seekingalphaNervGen Pharma Shares Rise After Buy Rating from TD Cowen
- 8.505-26Newsfilter
NervGen's NVG-291 Shows Significant Improvement in Gait Quality
9.505-22seekingalphaStock Futures Slightly Rise as Investors Monitor Iran Peace Talks
- 8.505-22seekingalpha
NervGen Pharma Announces Public Offering of 24 Million Shares
NGEN FAQ — answered by Alphio AI
NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in developing treatments to promote nervous system repair in the settings of neurotrauma and neurologic disease. NVG-291 is in a Phase 1b/2a clinical trial in spinal cord injury and has undertaken preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI). Its NVG-291 is a therapeutic peptide targeting nervous system repair. It operates in the Healthcare sector.
Nervgen Pharma appears to be a good buy right now, given its current price of $2.28, a recent RSI of 83.719 indicating strong momentum, and a projected price target of $15 from H.C. Wainwright. The positive catalysts include a public offering that raised $60 million for clinical studies and a Buy rating from TD Cowen, projecting peak sales of $1.1 billion for NVG-291. However, the main risk is the significant year-to-date change of -63.52%, indicating past volatility and potential investor concerns.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.